<DOC>
	<DOC>NCT02011659</DOC>
	<brief_summary>To compare postoperative nausea and vomiting (PONV) and perioperative outcomes of gynecologic patients undergoing laparoscopic surgery after scheduled administration of intravenous Ramosetron during hospital stays. - Randomized controlled arm : Placebo versus Ramosetron injection - Administration schedule : immediate postoperative status, 12 hrs after surgery, 36hrs after surgery</brief_summary>
	<brief_title>Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy</brief_title>
	<detailed_description>Surgical outcomes including operative time, blood loss, Hb change, postoperative pain, nausea/vomiting scale, times of rescue therapy, and complications</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Adenomyosis</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Age: 18&lt; or =, = or &lt;70 with benign gynecologic disease ASAClass III Nodefinite malignancy by US, CT/MRI, CA 125 &lt; 500IU/ml Nonsmoker Conversion to laparotomy Hx of malignancy Smoker Suspicious malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Ramosetron, postoperative nausea and vomiting, laparoscopy</keyword>
</DOC>